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Everywhere you look, the high cost of prescription drugs is mak-
ing news.'
I. INTRODUCTION
[S]eniors across the nation are searching for ways to cut their
drug bills. They are buying drugs much more cheaply in foreign
countries.2
A growing number of Americans who do not have a prescription
drug benefit and have earnings too high to qualify for various state
prescription drug programs have been rushing to Canada to fill their
prescriptions.3 This phenomenon is especially true for senior citizens
who qualify for Medicare but cannot afford to purchase supplemental
insurance to cover the price of prescription drugs.4 States across the
nation neighboring Canada have organized bus trips for the elderly to
buy cheaper drugs in Canada; price limits imposed by the Canadian
government have resulted in substantially lower prices.' The National
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Council of Senior Citizens charters "Prescription Bus Trips" to Can-
ada in response to the high cost of prescription drugs, and to make a
statement about the high cost of drugs in the United States.6
Compelling stories illustrate the plight of those who are adversely
affected by the soaring prices of prescription drugs. For example, a
woman suffering from high cholesterol in Maine scrambled to pick up
one of her cholesterol pills when she dropped it on the floor because
she knew that money was running right out of her hands if the pill was
not retrieved.7 Similarly, another woman was taking the prescription
drug Tamoxifin for breast cancer and claimed the drug costs almost
six times as much at her local pharmacy than it does in Canada.'
These situations illustrate why states across the United States are
trying to find ways to make prescription drugs more affordable.9
States' efforts to provide prescription drug relief took on added impor-
tance in 2001 after Congress failed to reach a compromise on a federal
program.' ° However, in late August 2001, an announcement that the
federal budget surplus had all but evaporated dashed hopes that a fed-
eral program will be funded."
One of the most controversial, yet most praised, solutions to ex-
orbitant prescription drug prices comes from Maine; the first state in
our nation to pass a price control law for prescription drugs. 12 The law
is called the Maine Act to Establish Fairer Pricing for Prescription
Drugs.'3 The issue emerged in Maine out of concern that many citi-
zens who were not Medicaid recipients could not afford necessary pre-
scriptions."' The bill that created the Act was also submitted in re-
sponse to senior citizens traveling hundreds of miles to Canada to
purchase prescription drugs.'" Meanwhile, the National Conference of
6. King, supra note 2.
7. Diana Graettinger, Seniors Cross Border to Fill Prescriptions; Trek to Canada Protests
High Drug Prices in U.S., BANGOR DAILY NEWS, Aug. 29, 2000, at 1.
8. Id.
9. See National Conference of State Legislatures, Health Care Program, 2001 Prescription
Drug Discount, Bulk Purchasing, and Price-Related Legislation, at http://www.ncsl.org
/programs/health/drugdiscOl.htm (last updated June 27, 2002) [hereinafter NCSL 2001].
10. Evan Osnos, Maine Fights Drug Costs; States Watch Suits Over Price Controls for Pre-
scriptions, CHI. TRIB. Sept. 2, 2001, at C1.
11. Id.
12. Me. Rev. Stat. Ann. tit. 22, § 2681 (2000).
13. 2000 Me. Laws 786 (S.P. 1026) (L.D. 2599).
14. PhRMA v. Concannon, 249 F.3d 66, 71 (1st Cir. 2001), cert. granted, PhRMA v. Con-
cannon, 122 S.Ct. 2657 (2002).
15. Maine Rx Express, Join our Fight for Fair Prescription Drug Prices, at http://www.
rxmaine.com/home/index.cfm (last visited July 29, 2002) [hereinafter Maine Rx Express]. Sen-
ior citizens are often the hardest hit by increasing prescription drug costs since they are the
pharmaceutical industry's largest consumer. Id.
[Vol. 26:169
Prescription Drug Price Control in Washington
State Legislatures reported that thirty-four states have considered leg-
islation in the past two years for discount, rebate, or price control pro-
grams that would limit prices in ways similar to new legislation
adopted in Maine. 6 In the year since Maine passed its law, price con-
trols have been considered by legislators in over fourteen states. 17
Maine's proposed solution is getting reactions from all over the coun-
try, but the legislation is on hold while the Act is being challenged by
the pharmaceutical industry in PhRMA v. Concannon."8 The case is
currently on appeal from the United States District Court of Maine,
which held that Maine's price control law was constitutional. 9 Many
states await the final ruling to decide whether to adopt a prescription
drug financing scheme modeled after Maine's recent legislation.
The problem is clear: Current prescription drug pricing method-
ologies across the nation are inadequate, and purchasing prescription
drugs in Canada is not a long-term solution to the problem of escalat-
ing drug costs for the citizens of Washington State.2" As a fellow
northern border state with Canada, Washington should adopt similar
legislation as the Maine Act in order to provide easy and affordable
access to prescription drugs. Continuous tension over the last few
decades between providing access to the latest efficacious treatments
while controlling rising health spending makes this issue particularly
important.2' In an effort to take responsibility for providing health
care solutions, Washingtonians, and all Americans, are discovering
how price controls work in Canada.22
Section II of this Note will discuss Canada's prescription drug
pricing scheme and why prescription drugs cost significantly more in
the United States. Section III will discuss PhRMA v. Concannon,23 in-
cluding an analysis of the parties' arguments on price controls for pre-
scription drugs. Section IV will illustrate that Washington's current
role in the battle on prescription drug pricing is inadequate to provide
accessible and affordable prescription drugs for its citizens. Section V
concludes with the proposal that Washington adopt new legislation
modeled after the Maine Act to Establish Fairer Pricing for Prescrip-
16. NCSL 2001, supra note 9.
17. Id.
18. 249 F.3d 66.
19. Id. at 85.
20. See Oh Canada, supra note 3.
21. J.D. Kleinke, Health Affairs: Prescription Drug Coverage Policy, 20(5) HEALTH
AFFAIRS 43, 44 (2001).
22. E.g. Devidas Menon, Pharmaceutical Cost Control in Canada: Does it Work?, 20
HEALTH AFF. 92, 93 (2001).
23. PhRMA, 249 F.3d 66.
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tion Drugs, which created the Maine Rx Program. In this manner,
Washington would have a better methodology to make prescription
drugs more affordable within its borders so that more citizens will
have access to necessary treatments without having to travel into Can-
ada in order to purchase less expensive prescription drugs.
II. PRESCRIPTION DRUG PRICING IN CANADA
A. Why Are Prescription Drugs in Canada So Much Cheaper?
Every American should get the same price that a Canadian gets
for American-made drugs.24
There is an overwhelming concern in the United States that
prices of prescription drugs are too high. 2S This claim is based on the
fact that Canadian drug prices are significantly lower than prices in
the United States.26 Moreover, politicians in the United States have
proposed measures to lower the cost of American drugs to a price
comparable to Canadian prices, an approach that is likely to be re-
ceived favorably by American patients, consumers, and healthcare
managers.27
Canada has managed to keep its prescription prices low by im-
posing government controlled price restrictions. 28 Differences in pre-
scription pricing can be attributed to the cost of research and devel-
opment. 29  As a means for recovering this cost, manufacturers may
charge different prices to different customers; "they often use meas-
ures of national income to guide them in setting their prices: higher
income countries pay more."3 The fact that Americans have become
increasingly wealthier is a reason one would expect to see higher prices
in the U.S.31 Further, pharmaceutical companies charge higher prices
in the United States to compensate for the risk of litigation.32 Canadian
24. Oh Canada, supra note 3 (quoting Hilary Clinton, Address at Rochester, N.Y., Feb.
10, 2000.
25. John R. Graham & Michael Walker, Commentary: Why are Drug Prices Lower in Can-
ada?, 6 AM. J. MAN. CARE 745, 745 (2000).
26. Id. In addition to brand-name drugs, less expensive generic drugs are offered in Can-
ada that are not offered in the U.S. Id.
27. Graham & Walker, supra note 25, at 745.
28. Oh Canada, supra note 3.
29. Graham & Walker, supra note 25, at 746.
30. Id.
31. Id.
32. Id.
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courts, however, do not experience the same superfluity of multibillion
dollar liability suits. 33
Another heated issue currently being debated revolves around
the drug industry's act of pushing new prescription medications on the
American public through direct-to-consumer advertising. While this
issue will be discussed later in this Note, the pharmaceutical industry
spent over $2 billion on television and magazine ads in 2000, which
many consider a ploy to get consumers to ask their physicians for the
latest, most expensive treatments. 34 This belief is supported by evi-
dence that prescription drugs advertised to consumers are now the
largest and fastest selling medicines.3" Recent research documenting
the trend in pharmaceutical spending revealed an escalation in the
volume of prescriptions being distributed, and a shift to using newer
drugs that are usually more expensive as the primary forces in the in-
crease of prescription drug expenditures.36  Consequently, many
Americans are forced to look elsewhere for less expensive prescription
drugs.
B. How Are Many American Citizens Purchasing Prescription Drugs in
Canada?
It is no longer necessary to travel to Canada to purchase pre-
scription medications at Canadian prices.37
It is important to know how Americans purchase prescription
drugs in Canada. First, they must have a prescription that is written
or co-signed by a doctor licensed in Canada.3" Accordingly, a number
of U.S. doctors practicing medicine in border states are also licensed in
Canada. 9 Citizens who receive prescriptions from Canadian doctors
are able to have the prescription filled in a Canadian pharmacy.4" Al-
though each consumer is only allowed a six-month supply, it is legal to
bring back or re-import prescriptions from Canada so long as they are
41for a patient's own use.
33. Id.
34. Schwab, supra note 1.
35. Fred Charatan, US [sic] Prescription Drug Sales Boosted by Advertising, 321 BRIT. MED.
J. 783 (30 Sept. 2000).
36. Health Net, Prescription Drug Expenditures in 2000: The Upward Trend Continues, 1
HEALTH CARE Focus 2 (2001).
37. RxPassport, Services: Bulletine! A NEW System for the Seattle area!, at 2.
38. Oh Canada, supra note 3.
39. Id.
40. Id.
41. Id.
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Seniors have also purchased their prescriptions from Canada on-
line.42 There are a handful of websites owned by Canadian pharma-
cies and other entrepreneurs where prescription drugs can be pur-
chased online at a savings of 20% to 50%. 4" While customers from the
U.S. enjoy a favorable exchange rate, ordering drugs online from Can-
ada is illegal for U.S. citizens.44 An exception to the rule is that citi-
zens can import three months of prescriptions from Canada for per-
sonal use if the same medications are not available in the United
States.4" Nevertheless, online pharmacies fill prescriptions for many
U.S. citizens.46
Purchasing necessary medications in Canada, or other low-cost
foreign countries, is only a temporary solution. And, not all drugs are
cheaper outside the U.S. For example, generic drugs in Canada are
often more expensive than generic drugs in the U.S.47 "The Canadian
Institute for Health Information reported recently that.., spending
on drugs now surpasses every other area of health care spending ex-
cept hospital services", including spending on doctor's services.48 Al-
though drug expenditures continue to rise in Canada, price control
measures have been effective.49
C. Why Are U.S. Drug Costs So Much Higher than Canada?
The overall evidence is that U.S. prices are by far the highest in
the worldso
Prescription drug costs are rising twice as fast as inflation, and
the pharmaceutical industry is the most profitable industry in the
42. Id.
43. Id.
44. Id.
45. Id.
46. Id.
So far U.S. authorities have been looking the other way since the Federal Drug Ad-
ministration is primarily concerned with large commercial shipments and doesn't have
the manpower to monitor individual shipments. While it is currently legal in Canada
for pharmacies there to fill prescriptions for U.S. citizens, some authorities are looking
to tighten the rules.
Id.
47. Graham & Walker, supra note 25, at 745.
48. Shelley Martin, Canadians Continue to Spend More on Drugs Than Doctors, 164
J.A.M.C. 1336 (May 2001).
49. Menon, supra note 22, at 99.
50. Dana A. Elfin, Drug Cost Debate Continues: Industry Opposes Price Controls, 11 THE
BUREAU OF NAT'L AFF. 484 (May 12, 2000) quoting Alan Sager, professor at Boston Univer-
sity's School of Public Health.
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world."1 In 1999, the cost of prescription drugs went up a record
17.4% over the previous year, and similar increases are forecasted for
coming years.52 "Americans spent $132 billion on prescription drugs
[in 2000] - an increase of $20.8 billion dollars (18.8%) over 1999. ' '13
The National Institute for Healthcare Management Foundation's
2001 study of prescription drug expenditures revealed that the overall
rise in spending was attributable to three key factors: (1) utilization,
(2) price, and (3) changes in the types of drugs used. 4 Statistics of the
aforementioned factors have shown a 42% increase in the number of
prescriptions written by doctors, while price increases and a shift to-
ward prescribing more expensive drugs have increased spending by58%. 5
Prescription utilization increased 53% from 1992-2000, com-
pared to a U.S. population growth of only 10%. 6 Additionally, pre-
scription prices reflect manufacturer price changes for existing drugs
and changes to newer and more expensive drugs, increasing on an av-
erage of 6.7% a year over the last decade. 7 Availability of the newer,
top-selling brand name drugs is affected by research and development
activities conducted by manufacturers and the National Institute of
Health. 8 Although research and development as a percentage of pre-
scription drug sales has remained relatively stable since the 1980s, s9
research and development spending increased $14 billion from 1988-
1998.60 These trends indicate that factors such as increasing prescrip-
tion use, rising prices, and growing reliance on newer, high-priced
brand name drugs have all contributed to the growth in spending for
51. Betsy Z. Russell, State Looks at Plan to Fight Drug Prices; Under measure, States Would
For Coalition to Negotiate Savings, SPOKESMAN -REVIEW, Mar. 10, 2001, at B1.
52. Id.
53. Fred Charatan, U.S. Spending on Prescription Drugs Rose by 19% in 2000, 322 BRIT.
MED. J. 1198, 1198 (2001).
54. NAT'L INST. OF HEALTH CARE MGMT., PRESCRIPTION DRUG EXPENDITURES IN
2000: THE UPWARD TREND CONTINUES, 11 figure 6 (May 2001), at: http://www.nihcm.org
/spending2000.pdf (last visited July 31, 2002) [hereinafter NIHCM].
55. Id. at 2. The foundation reported that manufacturer price increases for existing drugs
account for 22% of the overall increase in prescription spending from 1999-2000. An increase in
the number of prescriptions dispensed accounted for 42% of the overall increase. Changes in the
types of drugs used, with new high-priced drugs replacing old less-expensive drugs, accounting
for 36% of the increase. Id. at 11 figure 6.
56. Id. at 9.
57. THE KAISER FAMILY FOUND., PRESCRIPTION DRUG TRENDS: A CHARTBOOK, 2
(July 2000), at http://www.kff.org/content/2000/3019/PharmFinal.pdf.
58. Id. at 49.
59. Id. at 57, ex. 3.22.
60. Id. at 56, ex. 3.21.
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prescription drugs.61 Moreover, aging factors into a person's individ-
ual prescription use62 and plays a significant role in the national
growth in average prescription utilization.63
Advertising, however, is a major factor affecting prescription
drug utilization and the shift to higher-priced drugs.64 Consequently,"as the government has allowed more advertising of brand-name
drugs, more citizens have sought prescriptions." 61 In 1999, for exam-
ple, approximately "55 million people talked with doctors about pre-
scription drugs they saw advertised. 66 During that year, the pharma-
ceutical industry spent $13.9 billion on promotions alone.67  Since
1995, spending for direct-to-consumer advertising for newer, higher-
priced drugs has more than tripled. 6' Television advertising was 12
times greater in 1998 than in 1995, reaching $664 million.69 Since in-
creased advertising prompts an increase in demand for higher priced
medications, it will in turn, lead to an increase in the cost of prescrip-
tion drugs.
While the growth in advertising has played a role in rising pre-
scription drug costs,7" there are additional contributing factors, for in-
stance, medications as front-line therapy in treating illness.7 Increas-
ingly, people take more drugs for health conditions that were once
treated with surgery and long hospital stays.7 2 And, increased drug
use raises concerns regarding the overall costs and affordability of pre-
scription drugs nationwide.7 3
61. NIHCM, supra note 54, at 11 figure 6.
62. Id. at 10. People between the ages of 65-74 use 4 times as many prescription drugs as
those between 25-34. Id.
63. Id. (citing a study from Brandeis University indicating that between 1996 and 1999 the
number of new drug users rose "fastest among 45 to 64 year olds while the number of prescrip-
tions per person was rising fastest among people aged 65 and over." ).
64. Fred Charatan, supra note 35.
65. Pat Thibaudeau & Alex Deccio, Making Prescription Drugs Affordable, SEATTLE
TIMES, Feb. 25, 2000, at B5.
66. Id.
67. Frank Davidoff, Editorial: The Heartbreak of Drug Pricing, 134 (11) ANNALS OF
INTERNAL MED. 1068 (5 June 2001). Spending on promotions "included about one drug "de-
tail" salesperson for every 10 U.S. doctors, $2 billion on direct-to-consumer advertising, and
more than $7 billion in "free" drug samples." Id.
68. THE KAISER FAMILY FOUND., PRESCRIPTION DRUG TRENDS, (Sept. 2000), at:
http://www.kff.org/content/2000/3057/PrescriptionDrugsFactSheetPDF.pdf (last visited July
31, 2002).
69. Id.
70. Id.
71. Thibaudeau & Deccio, supra note 65.
72. Elfin, supra note 50, at 486.
73. THE KAISER FAMILY FOUND, supra note 68.
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Prescription drug costs in the U.S. are the greatest driver of
health care inflation nationwide, rising twice as fast as health care costs
in general. 4 "The numbers are even more striking when compared to
the industry's overall profitability."75 For instance, in 1999 the indus-
try achieved a profit of 18.6% on $125 billion sales "a larger profit
margin than most other sectors of the U.S. economy."76  Measures
must be taken to control prescription drug costs. The task, therefore,"is twofold: (1) to curb the growth of state spending on prescription
drugs without compromising the quality of care", and (2) provide a
method "for ways to help our older citizens find affordable prescrip-
tions" legally.7
III. PHRMA V. CONCANNON-MODEL LEGISLATION?
A. Summary of the Case
On May 11, 2001, the Act to Establish Fairer Pricing for Pre-
scription Drugs established the Maine Rx Program. 8 The bill creat-
ing the statute was enacted in response to the escalating number of
senior citizens traveling hundreds of miles on bus trips to buy cheaper
prescription drugs in Canada. 9 With prescription drug costs rising at
an average of 18-19% in the U.S.,"0 many people were forced to choose
between paying for their medications or for essential items such as
food, utilities and rent.81 "The problem is especially severe for senior
citizens, many of whom are on fixed incomes, because Medicare does
not cover the prescription costs."82 The Maine Legislature was con-
cerned that citizens who were not Medicaid recipients would not be
able to afford necessary prescription drugs.8
The essential problem shared by Maine and many other states is,"given the rising cost of prescription drugs, how [to] extend access to
those drugs for people who don't have private insurance but earn too
74. Thibaudeau & Deccio, supra note 65.
75. Davidoff, supra note 67, at 1068.
76. Id.
77. Thibaudeau & Deccio, supra note 65.
78. Me. Rev. Stat. Ann. tit. 22, § 2681 (2001). This "program" was established to reduce
prescription drug prices for residents of Maine. Id.
79. Maine Rx Express, supra note 15.
80. NIHCM, supra note 54, at 2.
81. Congressman Tom Keefe, An Investigation of Prescription Drug Price Disparity in the 5h
Congressional District of Washington, at http://www.tomkeefe.org/html (last visited Jul. 24,
2002).
82. Id.
83. PhRMA v. Concannon, 249 F.3d 66, 71 (1' Cir. 2001).
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much to qualify for Medicaid."84 Maine's mandatory drug rebate pro-
gram was created to address this problem.85
Under the Program, the State serves as a pharmacy benefit man-
ager by establishing manufacturer rebates and pharmacy discounts to
reduce prescription drug prices to consumers.86 The Act authorizes
the Commissioner of Maine's Department of Health Services to nego-
tiate rebate agreements with manufacturers so that participating
Maine pharmacies can offer prescription drugs at a discounted price.87
Proceeds raised from rebate payments are deposited into a special fund
used to reimburse pharmacies offering discounted prescription drugs
to consumers. 88 All Maine residents who enroll in the Program are
eligible to purchase prescription drugs from participating pharmacies
at this discounted rate. 9
Although pharmacy involvement in the Program is voluntary,
non-participating manufacturers and labelers are subject to pre-
authorization restrictions on their products.9" The State Medicaid
administrator cannot authorize a drug to be dispensed that is subject
to prior authorization to a Medicaid beneficiary without approval.91
Additionally, the Act provides that manufacturers who do not enter
into rebate agreements with the Commissioner will have their names
released to health care providers and the public.92 Manufacturers who
fail to achieve certain price reductions by July, 2003 will also be sub-
ject to state controls.93
Pharmaceutical Research & Manufacturers of America (PhRMA)
brought suit in the United States District Court of Maine against the
Commissioner of the Maine Department of Human Services and the
Maine Attorney General alleging that the Act violated the dormant
Commerce Clause and was preempted by the federal Medicaid Statute
84. Wayne J. Guglielmo, Rx Price Controls: Maine Gets a Go-Ahead, MED. ECON., July 9,
2001 at 23-24.
85. Id. at 23.
86. Me. Rev. Stat. Ann. tit. 22, § 2681(1) (2001).
87. PhRMA, 249 F.3d at 71. When negotiating the rebate, the Commissioner is to take in
to account the rebate amount calculated under the Federal Medicaid Program, 42 U.S.C. §
1396r-8 (2001), and to use "best efforts" to obtain a rebate in the same amount. PhRMA, 249
F.3d at 71; see also Me. Rev. Stat. Ann. tit. 22, § 2681(4)(A)-(C), and § 2681(5) (2001).
88. Id.
89. Id.
90. Me. Rev. Stat. Ann. tit. 22, § 2681(7). The drugs of all noncompliant manufacturers
are subject to the prior authorization requirements in the State Medicaid program. Id.
91. PhRMA, 249 F.3d at 72.
92. Id. at 71-72.
93. Guglielmo, supra note 84, at 23-24.
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under the Supremacy Clause.94 The District Court issued a prelimi-
nary injunction and found the Act unconstitutional on both grounds,
holding that (1) the Act had an extraterritorial reach in that it regu-
lated out-of-state revenues received by pharmaceutical manufacturers
from out-of-state distributors, thereby violating the dormant Com-
merce Clause and (2) the Act was preempted by the Supremacy
Clause because it conflicted with the purpose of the federal Medicaid
program.95
However, a three-judge panel sitting for the First Circuit Court
of Appeals in Boston, concluded that Maine's Rx Program to establish
Fairer Pricing for Prescription Drugs was constitutional.96
B. The Circuit Court's Reasoning
To determine the validity and constitutionality of the Maine Act
the 1" Circuit court conducted a four-part analysis including the issues
of (1) standing, (2) preemption, (3) the dormant Commerce Clause,
and (4) other preliminary injunction factors.97 First, the court re-
viewed the question whether PhRMA had prudential standing to chal-
lenge the prior authorization provision of the Act. 98 Because the inter-
ests to be protected in this case were created by the Supremacy Clause
and not by the federal Medicaid statute, the court concluded that
PhRMA had prudential standing.99 The Third Circuit recently
opined that an entity seeking the protection of the Supremacy Clause
does not need prudential standing."' In this regard, the court estab-
lished that PhRMA could assert the rights of Medicaid recipients in
this action so long as it had prudential standing grounded in the Su-
premacy Clause.10 '
94. PhRMA, 249 F.3d at 72.
95. Id.
96. Id. at 85.
97. Id. at 72-85.
98. Id. at 72-74. The Supreme Court held that to have prudential standing, a plaintiff
must fall within the relevant "zone of interest," which is determined by discerning the interests
"adequately" to be protected by the statutory provision and whether the plaintiffs affected inter-
ests are among them. Nat'l Credit Union Admin. v. First Nat'l Bank & Trust Co., 522 U.S.
479, 492 (1998) citing Data Processing Service Organization, Inc. v. Camp, 397 U.S. 150, 153
(1970).
99. PhRMA, 249 F.3d at 73-74.
100. Id. at 73 (quoting St. Thomas-St. John Hotel & Tourism Ass'n, Inc. v. Government
of the U.S. Virgin Islands, 218 F.3d 232, 241 (3d Cir. 2000)).
101. PhRMA, 249 F.3d at 74.When a party has standing to challenge the lawfulness of a
statute, it is "entitled to assert those concomitant rights of third parties that would be 'diluted or
adversely affected; should [its] constitutional challenge fail and the statute[ ] remain in force."'
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Second, the court considered whether the Maine Act was facially
subject to implied conflict preemption under the Supremacy Clause." 2
While a federal law may expressly or impliedly preempt state law un-
der the Supremacy Clause, only implied conflict preemption was at is-
sue in this case.1"3 The court did not consider express preemption be-
cause the Medicaid statute did not contain explicit language,
forbidding the Maine Act.0 4 Implied preemption may be "field" or"conflict"; here the court addressed "conflict" preemption. To resolve
the implied preemption question, the court scrutinized the state regu-
lation to ascertain if it was consistent with the Medicaid statute by ex-
amining the structure and purpose of the statute in its entirety. 105 The
court found no conflict between the Maine Act and Medicaid's struc-
ture and purpose because the policy of both Acts were consistent-to
provide medical services to those who do not have sufficient resources
to subsidize these services on their own, 10 6 while reducing Medicaid
expenditures by making prescription drugs more accessible to the un-
insured.0 7
The court further noted that the letter and intent of the Medicaid
statute does not prevent states from imposing prior authorization re-
quirements, but explicitly permits it.' ° As such, the Maine Act in-
corporated the requirements of the Medicaid program by explicitly
stating that prior authorization requirements would be imposed in the
Medicaid program to dispense prescription drugs. 9 After holding
Id. (citing Craig v. Boren, 429 U.S. 190, 195 (1976) (quoting Griswold v. Connecticut, 381 U.S.
479, 481 (1965))).
102. PhRMA, 249 F.3d at 74 quoting U.S. Const. art. VI, cl. 2, "stating that federal law
'shall be the supreme law of the Land ... any Thing in the Constitution or Laws of any State to
the Contrary not withstanding."' Id.
103. PhRMA, 249 F.3d at 74.
104. Id. at 74 n. 6 (quoting Grant's Dairy-Me., LLC v. Comm'r of Me. Dep't of Agric.,
Food & Rural Res., 232 F.3d 8, 15 (1" Cir. 2000)). Express preemption applies when "a federal
statute explicitly confirms Congress's intention to preempt state law and defines the extent of
that preclusion." The court noted the doctrine of implied "field" preemption did not apply be-
cause Medicaid is a cooperative federalism program so Congress explicitly allows some room for
State law. PhRMA, 249 F.3d at 74 n. 6 (citing Gade v. Nat'l Solid Waste Mgmt. Ass'n, 505
U.S. 88, 98 (1992)).
105. PhRMA, 249 F.3d at 74-79.
106. Id. at 78.
107. Id. at 75. The court reasoned that when people cannot afford to purchase necessary
medication, their conditions could worsen, forcing them into poverty and right into the hands of
the Medicaid program at a higher cost of treatment, which could have been prevented had earlier
more affordable services been available in the beginning. Id.
108. Id. at 75 (citing 42 U.S.C. § 1396r-8(d)(1)(A)).
109. PhRMA, 249 F.3d at 75. The court read the language in the Act to limit its applica-
tion to circumstances in which prior authorization is acceptable under Medicaid. Id.
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that the Maine Act was not preempted by the federal Medicaid stat-
ute, the court addressed the dormant Commerce Clause question. 110
Under the dormant Commerce Clause, states are prohibited from
acting in a way that burdens the flow of interstate commerce."' To
determine whether a statute violates the dormant Commerce Clause,
at least one of several levels of analysis applies, depending on the state
legislation's effect and reach." 2 Here, the court reviewed all three: (1)
when a state statute has an extraterritorial reach it is a per se violation
of the Commerce Clause;" 3 (2) when a state statute discriminates
against interstate commerce, a strict scrutiny analysis is applied,
whereby a state statute will be per se invalid unless the state can show
that a legitimate local purpose will not be adequately served by any
reasonable nondiscriminatory alternative; 1 4 and (3) when a state stat-
ute regulates independently and only has incidental effects on inter-
state commerce, a lower standard of scrutiny is applied under a
balancing test."' Respondents contended that the Maine Act was per
se violative of the Commerce Clause, while appellants asserted that the
Act independently regulated an in-state matter that merely had an in-
cidental effect on interstate commerce." 6
The court, therefore, considered both levels of analysis." 7 As to
per se invalidity, it did not agree with the respondent that the Maine
Act had an extraterritorial reach on matters outside the state."' The
court concluded that the Maine Act did not regulate the price of trans-
actions outside the state either by its "express terms or inevitable ef-
fect,"'' 9 and it did not impose controls on out-of-state transactions. 120
While the respondent asserted that the effect of the Act would be
to regulate transactions between manufacturers and wholesalers,
which are out-of-state activities, the court reasoned that an incidental
negative effect on manufacturers' profits did not amount to a regula-
tion of those profits.' 2' Nor did the court find that the Act interfered
110. Id. at 79.
111. Id. (citing Okla. Tax Comm'n v. Jefferson Lines, Inc., 514 U.S. 175, 179-180 (1995)).
112. PhRMA, 249 F.3d at 79.
113. PhRMA, 249 F.3d at 79 (citing Healy v. Beer Inst., 491 U.S. 324 (1989)).
114. PhRMA, 249 F.3d at 79 (citing Or. Waste Sys., Inc. v. Dep't of Envtl. Quality of Or.,
511 U.S. 93, 100-01 (1994)).
115. PhRMA, 249 F.3d at 80 (citing Pike v. Bruce Church, Inc., 397 U.S. 137, 142 (1970)).
116. PhRMA, 249 F.3d at 80.
117. Id.
118. Id. at 82.
119. Id. at 81.
120. Id. at 81-82.
121. Id. at 82. The court noted that the Act did not regulate transactions between manu-
facturers and wholesalers, but amounts to a "best efforts" obligation on the part of the Commis-
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with regulations in other states; the Act did not regulate prices, but
simply negotiated rebates.122 The court reasoned that all activities
regulated by the Act occurred in the state, which included: the pur-
chase of prescription drugs to trigger the rebate; the negotiation of a
rebate amount; and the subjection of a manufacturer's drug to prior
authorization, as well as, the release of the manufacturer's name to
health care providers and the public. 23 Thus, the regulation of these
in-state transactions could not amount to an extraterritorial reach so
the Act was not per se invalid under the Commerce Clause."'
The court concurred with the State that the Act regulated even-
handedly and had only incidental effects on interstate commerce. 2 '
The court opined that there was a presumption in favor of the validity
of the Act that would be upheld unless it imposed a burden on inter-
state commerce that was excessive in relation to the putative local
benefits.'26 In this regard, the court undertook a lower level of scru-
tiny, known as the Pike balancing test, 127 to balance the nature of the
putative local benefits promoted by the Act against the burden it
placed on interstate commerce, and to determine whether the burden
was "clearly excessive" as compared to the putative local benefits. 2 '
The court found that the enforcement of the Act could negatively im-
pact manufacturers' profits but did not find an excessive burden on
interstate commerce when compared to the local benefits. 29  It was
concluded that the local benefit of providing increased access to pre-
scription drugs outweighed the possible burden on interstate com-
merce of lost profits for manufacturers. 3 °
In its final analysis, the court gave deference to the constitutional
notion of federalism, favoring a state's right to experiment with social
sioner to negotiate an initial rebate amount equal or greater than the rebate offered under Medi-
caid. Essentially, the Act seeks to offer a negotiated rebate agreement between a manufacturer or
labeler that sells prescription drugs in the low-cost drug program in Maine. Id.
122. Id. at 82.
123. Id.
124. Id. at 82-83.
125. Id. at 84.
126. Id. at 83-84 (quoting Pike, 397 U.S. at 142 (1970)).
127. PhRMA, 249 F.3d at 83-84. Courts undertake this balancing approach when a le-
gitimate local interest is found, making the question one of degree. The extent of the burden that
will be tolerated depends on the character of the local interest involved and whether it can be ad-
vanced with a low impact on interstate transactions. Id.
128. Id.
129. Id. at 84. The court recognized the difficulty in foreseeing what could arise from the
enforcement of the Act, which is why a Pike balancing test of the possible effects rather than the
actual effects the Act was applied. Id.
130. Id.
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and economic matters without risk to the rest of the nation.' In es-
sence, Maine could be viewed as a laboratory for which this new Act,
if adopted, could serve as a model for similar legislation in other
states. 132
C. The Parties' Views on the Maine Rx Program
1. The Opponents' View: A Bad Idea for Patient Welfare and
Innovation
As a spokesman for the pharmaceutical industry, PhRMA la-
beled the Maine Rx Program a "bad idea" and encouraged other states
not to follow the Maine Model.'33 Although PhRMA's constitutional
challenge was unsuccessful, the pharmaceutical industry remains
steadfast in its campaign against employing the Maine Rx Program, as
well as other programs that seek to impose price controls on prescrip-
tion drugs.134
One of the industry's main concerns is that a prior authorization
requirement places an administrative burden on physicians and pa-
tients by interfering with the delivery of Medicaid services.'3S It main-
tains that the Maine Rx Program creates a high likelihood of harm
from improper medication prescriptions, which unnecessarily burdens
physicians, and creates needless inconvenience for Medicaid recipi-
ents. 136  Furthermore, prior prescription drug authorization without
considering safety or efficacy could lead to more prescriptions that are
less safe and efficacious. 137
131. Id. at 85.
132. Id.
133. States Should Reject the Maine Price Control Law as Bad for Patients and Bad for the
Economy at http://www.phrma.org/press/newsreleases/2000-06-20.44.phtml (last visited July
29, 2002) [hereinafter Reject].
134. Id.
135. PhRMA, 249 F.3d 66 at 76.
136. Id. at 77-78. PhRMA contends that the Maine Rx Program will harm Medicaid re-
cipients by inhibiting access to their physician's first-choice medications. The district court
agreed, and concluded that the Maine Act conflicted with the Medicaid provision setting forth a
general requirement provision that a state Medicaid plan contain safeguards to assure that care
and service will be provided consistently with the "best interests of the recipients." Id. at 77
quoting 42 U.S.C. § 1396a(a)(1 9). The Court of Appeals, however, did not find sufficient basis
for concluding that the Maine Act facially controverts the Medicaid goal of "best interests." Id.
at 78.
137. Id. at 78.
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Another concern is that research and development will be nega-
tively affected.'38 While the pharmaceutical industry is extremely
profitable, it asserts that substantial profits are crucial to the industry's
research and development efforts; the average cost to research and de-
velop one new drug is $500 million, 3 9 taking on average twelve to fif-
teen years to reach the market.14 ° Extensive and costly research is re-
quired before the benefits of a new drug are known.' Additionally,
many new drug developments fail after considerable costs are in-
curred, including time value and fiscal support.'42 For these reasons,
intractable problems arise when developing price controls because
methodology cannot rest on independent, predictable standards such
as the costs or benefits of specific drugs.'43 The pharmaceutical indus-
try contends that without objective standards, incentives would be
created for price regulators to decrease drug costs toward marginal
costs of production and delivery, which is significantly below adequate
levels to reward innovative research. 44
Consequently, the downward biased price setting device would
apply with specific force to the few successful schemes that produce
innovative prescription drugs, whose prices would not be predeter-
mined by regulatory authorities until after research and expenditures
are incurred and the new drugs can be sold. 4  The pharmaceutical
industry believes that drug manufacturers would expect price controls
to reduce the potential gains from new and improved drugs, which
could substantially decrease incentives to pursue innovative re-
search.'46 In effect, "price control systems.., tend to create disincen-
tives for innovative products; they are systems that tend to shelter
older medicines, and tend to disincentivize new medicines."'' 47
In essence, the pharmaceutical industry argues that price controls
do not work because they result in decreased access and rationing of
necessary drugs, and they slow the development of new and improved,
138. John E. Calfee, Pharmaceutical Price Controls and Patient Welfare, 134 ANNALS OF
INTERNAL MED. 1060, 1060 (2001).
139. Id. at 1061. The $500 million dollar figure takes into consideration the costs of re-
searching a particular drug, including the drug failures that lead up to the development of that
drug, as well as inflation. Elfin, supra note 51, at 484-85.
140. Elfin, supra note 50, at 484.
141. Calfee, supra note 138, at 1060-61.
142. Id. at 1061.
143. Id. at 1061-62.
144. Id. at 1062-63.
145. Id. at 1062.
146. Id. at 1062-63.
147. Elfin, supra note 50, at 485 (quoting Shannon Herzfeld, senior Vice President, Inter-
nat'l Affairs, at PhRMA).
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cost-effective drugs.'48 For these reasons, the pharmaceutical industry
claims that the Maine Act does not really help those that lack prescrip-
tion drug coverage, but harms those waiting for new developments
and treatments to help cure diseases.'49 Furthermore, the Act would
enable state bureaucrats to decide which drugs are best for patients
rather than doctors, resulting in an obstruction of the doctor-patient
relationship. 5 °
According to the pharmaceutical industry, the solution to pro-
viding more accessible and affordable prescription drugs is not a
patchwork of state price control proposals that attempt to slow the de-
velopment of new and better prescription drugs. 5 The solution, they
believe, is found in the adoption of federal legislation that would at-
tenuate insurance coverage to those without it. 152 In other words, the
pharmaceutical industry strongly supports congressional action that
expands drug coverage for those with a substantial need, such as sen-
iors and disabled citizens, by providing a choice of private-sector
plans.'53 This solution would help patients who need access to cur-
rently developed drugs without harming patients who need access to
drugs not yet developed.5 4
2. The Proponents' View: A State-Based Policy Solution for
Affordable Prescriptions
Without the Maine Rx Program, many needy citizens would
continue to be deprived of necessary medical care due to rising pre-
scription drug costs. 5 Given that affordability is crucial in providing
access to prescription drugs,5 6 proponents of the Maine Rx Program
assert that "this kind of innovative, state-based policy solution is the
only practical way of winning fair prescription prices for millions"'5 of
American citizens. Affordable drugs increase accessibility, which en-
hances the overall health of many citizens, encourages healthy com-
munities, and protects public health and welfare.'58
148. Reject, supra note 133.
149. Id.
150. Id.
151. Id.
152. Id.
153. Id.
154. Id.
155. PhRMA v. Concannon, 249 F.3d 66,84 (1st Cir. 2001).
156. Me. Rev. Stat. Ann. tit. 22, § 2681(1) (2001).
157. Maine Rx Express, supra note 15.
158. Me. Rev. Stat. Ann. tit. 22, § 2681(1) (2001).
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Furthermore, price controls will dampen the effects of price dis-
crimination, which often escalates drug prices at the expense of those
who rely on prescription drugs in order to maintain healthy lives."5 9
Drug manufacturers' pricing strategy "victimize those Americans who
are least able to afford it.' 161
As a result of this price discrimination, larger purchasers with
market power, such as Health Maintenance Organizations
(HMO's) and government customers, are able to purchase their
drugs at lower prices while senior citizens, who often have the
greatest need and the least ability to pay, must pay the highest
prices.16
With prescription drug costs rising, many citizens are forced to
choose between paying for their drugs and for life essentials such as
food, bills, and rent.16  This is especially problematic for senior citi-
zens who are not receiving necessary drugs because Medicare does not
cover the cost of prescriptions.'63 The problem is even worse for rural
seniors because they are 60% less likely to get necessary drugs, and
when they do receive these drugs, they are often times 25% more ex-
pensive. 64
As a result, many citizens are forced to cross the border into for-
eign countries like Canada to purchase the prescription drugs they
need. '6 The Maine Act will ease this burden, while significantly low-
ering the costs in this country.
Finally, proponents of the Maine Rx Program contend that the
pharmaceutical industry benefit from the implementation of price
controls.'66 As the most profitable industry in the world, "it can easily
absorb a modest slowdown in the rate of revenue growth without
compromising its own vigor or the overall quality of health care."' 67
While the industry argues that price controls would negatively impact
research and development for more effective and better quality drugs,"of the nine U.S. companies that manufactured the fifty top-selling
drugs, eight spent more than twice as much on advertising, marketing,
159. Congressman Bernard Sanders, Legislation: Three Bills Push for Prescription Drug Pric-
ing Reform, at http://www.Bernie.house.gov/prescriptions/index.asp (last visited July 23,
2002).
160. Id.
161. Id.
162. Id.
163. Id.
164. Id.
165. Sanders, supra note 159.
166. See Davidoff, supra note 67, at 1070.
167. Id.
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and administrative costs than they did on researching new drugs. '
The pharmaceutical industry, which evidently will not lower prescrip-
tion drug costs, has plenty of financing to overwhelm the media with
their advertising. 169
With the highest profit margin in the world, the pharmaceutical
industry is clearly in the business of making money. Because the in-
dustry allocates nearly comparable amounts of its 19% profit margin to
both advertising and research, 7 ' a decrease in the amount spent on
advertising could be achieved without a significant loss in the drive for
developing the latest and most efficacious medications.' 7' Even
though profits may suffer from a decrease in aggressive advertising,
the huge profit margin realized by the pharmaceutical industry leaves
plenty of latitude to continue funding research and development. In
other words, the reduction in revenue expected by the industry as a re-
sult of price control, could be compensated for by taking profits that
are used in advertising and putting it toward research and develop-
ment.
Lowering drug prices rather than increasing advertising to fix
their public image may be the right move for the industry, especially
because the industry lacks a positive public image.'72 Additionally, a
cut in drug prices might actually increase industry revenues.'73 Both
Merrill Lynch and the New England Journal of Medicine have re-
168. Prescription Drug Coverage Policy, HEALTH AFF. 61 (Sept./Oct. 2001), at
http://130.94.25.113/readeragent.php?ID=/usr/local/apache/sites/healthaffairs.org/htdocs/Li
brary/v20n5/s8.pdf (last visited July 31, 2002). The pharmaceutical industry runs millions of
dollars in newspaper, television, and radio advertisements. In addition, the pharmaceutical in-
dustry spends more money on campaign contributions and lobbying than any other industry.
During the 2000 election cycle, for example, it contributed approximately $4.4 million to De-
mocrats (a 66% increase over the 1998 election cycle) and approximately $14.9 million to Repub-
licans (a 141% increase over the 1998 election cycle). Center for Responsive Politics, at
http://www.opensecrets.org/industries/Indus.asp?ind=H4300 (last visited July 28, 2002). To-
tal contributions to Congress were $4.6 million. Id. at http://www.opensecrets.org
/industries/sunmary.asp?Ind=H4300&cycle=2000&recipdetail=A&sortorder=U. (last visited
July 23, 2002).
169. Congressman Bernard Sanders, Prescription Drug Pricing Reform, Help Fight the High
Cost of Prescriptions, at http://bernie.house.gov/prescriptions/index.asp. (last visited July 23,
2002).
170. For example, in 1999 the industry spent approximately $14 billion on promotion alone
and about $20 billion on the overall costs of development. Davidoff, supra note 67, at 1068; see
also Luke Timmerman, Demand, Marketing Drive Up Drug Price, SEATTLE TIMES, April 28,
2002, at A26 (stating that the pharmaceutical industry is the most profitable industry in the
world with a profit margin at 18.5% in 2001 with $20.8M on R&D and $30M on advertising).
171. Elfin, supra note 50.
172. Davidoff, supra note 67, at 1070.
173. D.Z. Jackson, Drug Price Cuts Won't Kill Industry, 22 BOSTON GLOBE, Sept. 22,
2000, at A27.
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ported that price cuts in the proposed 40% range will be more than
compensated for by increased sales volume.'74 In this regard, states
like Washington would benefit from enacting price control legislation
for its citizens.
IV. WASHINGTON'S ROLE IN THE BATTLE ON
PRESCRIPTION DRUG COSTS
I compared the cost of the top ten prescription drugs in Wash-
ington State to the cost of the same drugs in Canada. What I
found was outrageous-seniors would save an average of 64% by
purchasing their drugs in Canada. 175
The word is out, and more and more Washington residents seem
to be making the trip to Canada to cash in on the savings attributed to
the lower costs of prescription drugs. 176  According to RxPassport,
Washington has experienced a flow comparable to Maine of citizens
traveling across the border to receive cheaper prescription drugs. 177
For example, Washington citizens have organized bus trips to
Canada to purchase their prescriptions. Additionally, prescription
drug systems in Washington State such as RxPassport help residents
gain access to affordable drugs through physicians and pharmacies in
Canada.'78 Since its inception in 2000, RxPassport has reportedly
helped Americans save between 40-80% on their prescription drugs. 9
While the program initially required U.S. citizens to travel to Canada
to have their prescriptions authorized by a Canadian physician, it has
been updated under a new system called Cross Border Rx Services,
making travel to Canada no longer necessary.' This system allows
citizens in the Seattle area to purchase their prescriptions in the state
through a licensed physician who may order prescriptions from Can-
ada.'' The quality and cost of the new program is reportedly equal to
174. Id.
175. Oh Canada, supra note 3, (quoting Slade Gorton, former U.S. Senator of Washington
State).
176. Rx Passport, Your American Right to Affordable Medication,
http://www.rxpassport.com/services/services.html (paraphrasing a quote by Ross McLaughlin,
KIRO 7 Eyewitness News) (last visited August 30, 2002).
177. Id.
178. Id.
179. Id.
180. Id.
181. Id.
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the previous program, without the added inconvenience and expense
of traveling to Canada. 18 2
Despite the benefit this system offers to Washington residents,
there must be a more permanent solution to the high costs of prescrip-
tion drugs. Washington needs a state-based policy solution so resi-
dents no longer need to go through channels in a foreign country to
buy their necessary prescriptions.
The need for a new plan in Washington is clear considering that
an estimated one in five Washington residents do not have prescrip-
tion drug insurance, forcing them to pay the maximum cost for their
prescriptions. 83 Furthermore, medical advances have increased utili-
zation as well as prescription prices, compelling thousands of residents
to dig deeper and deeper into their pocketbooks to pay for these life-
prolonging drugs.' 84
Prescription drugs' rising costs also put pressure on the state to
increase expenditures to meet the health care needs of lower-income
families. 8 ' In this regard, there are dual pressures facing the state to
make prescription drugs more affordable for its neediest citizens, while
trying to control the cost of providing the most vital prescription
drugs. 186
A. What Has Washington Proposed to Combat the High Price of
Prescription Drugs? Is It Enough?
One in four Washington residents have no prescription drug in-
surance, and, as a result, pay top dollar for their prescriptions.'87
Concerned about the implications of rising drug costs, the Wash-
ington Legislature has reviewed a number of proposals to determine
what can be done to control cost increases. While other states offer
subsidy programs for prescription drugs, Washington has been beset
182. Id.
183. Beth Silver, Debate Over Drug Costs Heats Up, THE NEWS TRIBUNE, February
14, 2001, at Al. An estimated 1.25 million people (1 in 5 Washington residents) are without
prescription drug coverage, almost half of which are seniors. Id.; see Senator Rosa Franklin,
Senate Calls For Regional Strategy to Reduce Prescription Drug Costs, at
http://.sdc.wa.gov/franklin.htm.
184. The Bottom Line on PRESCRIPTION DRUG COSTS, at http://www.sdc.wa.gov/
Issue%20Briefs/bottomlineprescriptiondrugcosts.pdf (last visited August 30, 2002).
185. Id. During the 1999-2000 state budget period, for example, about 25% of the state's
general fund (about $5 billion) went toward the purchase of health care services. Furthermore,
total general fund spending on health care is expected to increase 20% during the next biennium
to $6 billion. Id.
186. Id.
187. Franklin, supra note 183.
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by unique circumstances, such as double-digit inflation in health care
and the Initiative 601 spending cap, which called for a creative solu-
tion."' First, the State proposed The Washington Pharmacy Access
Program,' 89 which would create a prescription drug insurance plan for
people who are aged sixty-five and older or disabled. The program
provides that enrollees would pay premiums and make subsidies avail-
able to low-income seniors. Second, the Bulk Purchasing Study9 ' calls
for researching the feasibility of consolidating the purchase and distri-
bution of prescription drugs for certain state-funded programs.
Third, there is a proposal for an Aggregate Purchasing Prescription
Drug Discount Program,' 91 which directs the State to consolidate drug
purchasing for all its health care and other programs, and provides
citizens aged fifty-five and older with eligibility for discounts negoti-
ated with manufacturers. Fourth, the Regional Purchasing Plan,'92
which calls upon northwestern states to investigate the feasibility of
managing prescription drug prices through cooperative strategies,
passed both houses during the 2002 regular session and has been filed
with the Secretary of State.'93 It must be noted, however, that the ag-
gregate purchasing program and the bulk purchasing plan did not pass
muster in the House. 194
Finally, and perhaps most importantly, Governor Gary Locke's
AWARDS Discount Program attempted to provide discounts to resi-
dents aged fifty-five and older who do not have a prescription drug
benefits. 9 ' For an annual fee of $15 per individual and $25 per fam-
ily, enrollees would receive a card allowing them to purchase prescrip-
tions at discounted prices through a prescription drug buyer's club.'
188. Robert L. Jamieson Jr., Rx for Cutting Drug Costs of Seniors, SEATTLE POST-
INTELLIGENCER, Aug. 30, 2000 at 2; see http://seattlep-i.nwsource.com/local/drug30.shtml.
189. Substitute Senate Bill 5030, available at: http://www.leg.wa.gov/pub/billinfo/2001-
02/Senate/5025- 5049/5030-s.pdf (last visited July 30, 2002).
190. Senate Bill 5027, available at: http://www.leg.wa.gov/pub/billinfo/2001-
02/Senate/5025-5049/5027.pdf (last visited July 30, 2002).
191. Senate Bill 5026, available at: http://www.leg.wa.gov/pub/billinfo/2001-
02/Senate/5025-5049/5026-s.pdf (last visited July 30, 2002).
192. Senate Joint Memorial 8001, available at: http://www.leg.wa.gov/pub/billinfo/2001-
02/Senate/8000-8024/8001_pl.pdf (last visited July 30, 2002).
193. Id.
194. Senator Rosa Franklin, Senate Calls For Regional Strategy to Reduce Prescription Drug
Costs, at http://sdc.wa.gov/franklin.htm (last visited July 30, 2002).
195. The Washington State Department of Health, AWARDS Program Prepares to Sign
Up Seniors, at http://doh.wa.gov/Publicat/2000_News/Awards.html. (last visited Jul. 23,
2002).
196. Id. If enrollees go to participating pharmacies, they will get discounts ranging from 12
percent to 30 percent. If they use mail service, on the other hand, they may receive an even big-
ger discount ranging from 20 percent to 49 percent. Id.
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Enrollees' purchases at participating pharmacies would be merged
with the buying power of the state Uniform Medical Plan to buy
drugs at significantly lower costs.'97 The AWARDS program was
challenged by pharmacists claiming the AWARDS program was un-
fair and would have forced them to provide discounts that would have
put them out of business. 9 The program was overturned in June,
2001, by Superior Court Judge Richard Strophy as beyond the author-
ity of the Health Care Authority.'99
The AWARDS program had several problems.2"' Although the
AWARDS program was a good first-step, it was the "wrong prescrip-
tion" for Washington because it placed the financial burden of dis-
counts entirely on community retail pharmacies."' Additionally, the
governor's proposed operating budget provided no fiscal support to
pay for discounts offered under the program. 212 The program would
have operated at no cost to the state.2" As a result, "community
pharmacists [were] expected to provide the discounts out of their
pockets. '20 4 Eighty-five percent of a prescription's retail price comes
from manufacturer's costs, 2° and 3% of the price comes from the
wholesaler. 26 After additional costs of rent, salaries, insurance, taxes,
etc., pharmacists would receive only a net 3.4% profit. 27 Conse-
quently, pharmacists could not possibly remain in business if they
197. Governor Gary Locke, Establishing a Washington State Alliance to Reduce Prescription
Drug Spending "AWARDS" Program, Exec. Order No. 00-04, available at:
http://www.governor.wa.gov/eo/eo_00-04.htm (last visited Jul. 24, 2002).
198. Judge Says No to Drug Program, THE SEATTLE POST-INTELLIGENCER, May 26, 2001
at 1(citing Coalition for Affordable Prescriptions for Seniors v. State of Washington, State of
Washington, No. 01 -2-00525-9 (Thurston Co. Super. Ct. 2001)); see Angela Galloway, Discount
Drug Program for Seniors Ruled Illegal, at http://seattlepi.nwsource.com/local/24836-drugs26.
shtml (last visited August 12, 2002).
199. Galloway, supra note 198. "[T]he executive branch lacks the authority to implement
the program without statutory authority. On June 22 the judge noted that state agency has au-
thority to 'implement joint purchasing strategies' that have 'potential application to all state-
purchased health services.' Because AWARDS 'does not involve state purchased health services
and therefore exceeds the authority' in state law." National Conference of State Legislatures,
Health Care Program: State Pharmaceutical Assistance Programs, at: http://www.ncsl.org/pro-
grams/health/drugaid.htm (last modified July 18, 2002).
200. See Senator Linda Evans Parlette, AWARDS program is wrong prescription for Wash-
ington, SEATTLE-POST INTELLIGENCER, Jan. 9, 2001 at 1; see http://www.src.wa.gov/news/
pr/2001/parlettege010401.htm, at 1 (last visited August 12, 2002).
201. Id.
202. id.
203. Id.
204. Id.
205. Id.
206. Id.
207. Id.
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were expected to subsidize prescription drug discounts. 2°" The
AWARDS program seemed to be a damaging quick fix that could
have destroyed any chance of producing its intended result: providing
access to affordable drugs.219
Other options for reducing drug prices and controlling expendi-
tures within Washington State include a national proposal to expand
Medicaid's prescription benefit to seniors, and a state-based policy so-
lution that would impose price controls on prescription drugs so that
they are offered at discounts to all citizens of the state.210
Whatever the final solution may be, one thing remains certain:
Washington State can, and must, proactively address the real problem
of skyrocketing prescription drug prices."'
B. Is the Maine Program a Solution for Combating High Prescription
Drug Prices in Washington State?
Although the 'Maine Rx Law' is the most comprehensive pre-
scription drug price control bill to be signed into law ... price
control bills have been proposed ... or enacted in 16 other
states. 212
While the federal government takes its time in deciding how to
solve the problem of escalating prescription drug costs, states are be-
ginning to address the problem themselves.21 3 Maine was the forerun-
ner. Obviously, a state-adopted policy does not solve the problem for
all Americans, but it is a good solution for the citizens of Washington
State.
The fundamental reason why Washington should adopt price
control legislation is the same for every state in America--citizens
want relief from high prescription drug costs. Additionally, no other
proposal in Washington State has passed without much explanation
from state legislators except that they were the "wrong prescrip-
tion. ' 21' Because Maine's price control program is different from theother proposed programs, it may finally be the right prescription.
208. Id.
209. Id.
210. The Bottom Line on PRESCRIPTION DRUG COSTS, at http://www.sdc.wa.gov/
Issue%20Briefs/bottomlineprescriptiondrugcosts.pdf (last visited July 30, 2002).
211. Parlette, supra note 200.
212. NCSL 2001, supra note 9. Nineteen state legislatures considered price control bills
between the years 1999 and 2001. Id.
213. Locke, supra note 197.
214. See Parlette, supra note 200.
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First, proponents of price controls claim that it is an innovative
state-based policy solution to provide fair prescription prices for mil-
lions of citizens.2"' A state solution will provide more immediate re-
sults for citizens rather than a federal solution. Citizens want relief,
and they want it now. More importantly, it makes a difference where
citizens buy their prescription drugs.
Second, local pharmacists are more knowledgeable about the
needs of their individual patients, decreasing the risks of improper
dosing and mixing of incompatible drugs.216 Generally, community
pharmacists know their customers' health history and out-of-state dis-
tributors do not.217 Furthermore, even though a state program may
not result in prescription drug prices equivalent to those available in
other areas, including Canada, it will at least lower prices enough to
make it less economical to travel far from home.
Third, proponents claim that price controls will dampen the ef-
fects of price discrimination, which often escalates drug prices at the
expense of those who rely on prescription drugs in order to maintain
healthy lives.218
Finally, proponents contend that the pharmaceutical industry
stands to benefit by the implementation of price controls.1 9
Several states are aware of the clear advantages of a price control
system, and they plan to adopt similar legislation to the Maine Rx
Program when the dust settles from PhRMA v. Concannon.22' Al-
though state-level price controls will lead to price disparities between
states, any legislation on a state-by-state basis will inevitably lead to
disparities. The issue of fairer pricing for prescription drugs is clearly
a nationwide problem, but it is up to individual states to decide what
is best for their own citizens.22' The best solution in Washington State
for combating the high price of prescription drugs is to adopt price
control legislation modeled after the Maine Rx Program.
215. Maine Rx Express, supra note 15.
216. Parlette, supra note 200.
217. Id.
218. See Keefe, supra note 81.
219. Jackson, supra note 173.
220. Physicians For a Nat'l Health Prog., Court Rules in Favor of Maine Rx Price Controls,
at: http://www.pnhp.org/Press/2001/courtrules6_4_01.htm (last visited Jul. 25, 2002).
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V. CONCLUSION
Now that the appeals court has wiped away the stigma of uncon-
stitutionality, we expect the Maine approach to move like wild-
fire across the country.222
Many states have been waiting for a court decision in Maine to
see what the future holds for fair-pricing legislation.223 National inter-
est is high due to concerns about the lack of insurance coverage for
prescriptions, particularly for the elderly, and rising spending for
drugs.2 24 Price increases for drugs currently on the market, increased
prescription utilization, and reliance on newer, more expensive drugs
have all contributed to growth in spending. 22S "[S]pending on pre-
scription drugs [in the U.S.] is expected to continue to rise rapidly,
reaching $243 billion by 2008. ' ' 226 Meanwhile, "drug costs in 2001 are
expected to continue to increase at double-digit rates", 227 rising twice
as fast as inflation.228 With these increases, policy makers will likely
continue to be pressured to address cost concerns.
The implications of rising drug prices are alarming. In the ab-
sence of some form of price control measure, higher cost sharing and
reduced drug benefits are likely. 229 Furthermore, many insurance
companies that do offer coverage for some prescription drugs may re-
duce or eliminate that drug coverage altogether to compensate for ris-
ing costs. 230 As a result, the health and well being of many Americans
will be jeopardized due to inability to afford their prescription drugs.
Consequently, American borders will continue to be crowded with
people seeking to purchase cheaper prescriptions in other countries.
These results are not only inconvenient, but also unnecessary.
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During the 2000 election campaign, the prescription drug cost
crisis was a major issue nationally and within Washington State.231
While there have been several proposals to cut prescription drug costs,
nothing has received as much attention as the Maine Rx Program. It
not only provides a solution for the nation's elderly who are the pri-
mary consumers of prescription drugs, but it also assists many unin-
sured and indigent citizens. In this regard, the Maine Rx Program
promotes the overall health and well being of citizens by affording
them the opportunity to receive a health benefit.
Although Washington State has seen its fair share of prescription
cost-cutting proposals, it should adopt legislation modeled after the
Maine Rx Program to provide better access to more affordable pre-
scription drugs for all citizens.
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